Amarin Corp‘s patent involves a method to reduce heart failure risk in subjects on statin therapy by administering 1-4g of eicosapentaenoic acid ethyl ester. A specific claim outlines administering 4g of ethyl icosapentate daily to increase EPA levels. GlobalData’s report on Amarin Corp gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Amarin Corp, Cancer treatment biomarkers was a key innovation area identified from patents. Amarin Corp's grant share as of May 2024 was 39%. Grant share is based on the ratio of number of grants to total number of patents.
Method for reducing heart failure risk with ethyl icosapentate
A recently granted patent (Publication Number: US11986452B2) outlines a method for reducing the risk of heart failure in individuals with specific baseline triglyceride and eicosapentaenoic acid (EPA) levels. The method involves administering approximately 4g of ethyl icosapentate per day to increase the subject's EPA level to at least 104 µg/mL. This approach aims to reduce the risk of heart failure, particularly in cases of new heart failure or those requiring hospitalization, by potentially lowering the risk of cardiovascular events such as myocardial infarction, stroke, and unstable angina. The method also considers the subject's existing cardiovascular health status, including established cardiovascular disease or high risk factors.
Furthermore, the patent details the composition of the pharmaceutical formulation containing ethyl icosapentate, emphasizing the high concentration of omega-3 fatty acids in the product. The method specifies the dosage and duration of ethyl icosapentate administration required to achieve the desired increase in EPA levels, ranging from 104 µg/mL to 175 µg/mL. Additionally, the method highlights the potential benefits of combining this treatment with statin therapy for individuals at risk of cardiovascular disease. Overall, the patent provides a structured approach to reducing the risk of heart failure by targeting specific baseline EPA levels and triglyceride levels in individuals, potentially offering a preventive strategy for cardiovascular events.
To know more about GlobalData’s detailed insights on Amarin Corp, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
